Search results
Results from the WOW.Com Content Network
Antileukemic drugs, anticancer drugs that are used to treat one or more types of leukemia, include: [1]. 6-Mercaptopurine; 6-Thioguanine; Arsenic trioxide; Asparaginase; Cladribine ...
Malignant melanoma of the extremities, multiple myeloma, conditioning treatment before haemopoietic stem cell transplant. Myelosuppression, pulmonary fibrosis and pneumonitis (uncommon), skin necrosis (uncommon), anaphylaxis, hepatic sinusoidal obstruction syndrome and SIADH. Secondary malignancies. [16] Streptozotocin: IV, PO: Alkylates DNA.
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
Non-Hodgkin’s lymphoma (NHL) is one of the most common forms of blood cancer.1 The American Cancer Society estimates that about 81,560 people in the U.S. will be diagnosed with NHL and about ...
In 1966, the organization was renamed Leukemia Society of America. In 1968, the Leukemia Society of America published Closing In, Research on Leukemia, a book summarizing its progress in fighting leukemia. [8] In 1968, the Patient Services Committee created the Patient Aid Programs that helped cover patient medications, lab fees, blood ...
In many cases, Imatinib can induce a complete cytogenetic response (CCyR) and major molecular response (MMR) and many patients can have a long-term remission. It is also used to maintain remission in chronic phase CML patients. While Imatinib is a very effective treatment for CML and some types of ALL, it is not a cure for leukemia.
Studies of the cardioprotective nature of dexrazoxane, provide evidence that it can prevent heart damage without interfering with the anti-tumour effects of anthracycline treatment. Patients given dexrazoxane with their anthracycline treatment had their risk of heart failure reduced compared to those treated with anthracyclines without dexrazoxane.
The first list was published in 1977 and included 208 medications. [8] [2] [9] The WHO updates the list every two years. [10] There are 306 medications in the 14th list in 2005, [11] 410 in the 19th list in 2015, [10] 433 in the 20th list in 2017, [12] [13] 460 in the 21st list in 2019, [14] [15] [16] and 479 in the 22nd list in 2021.